Form 4: Cogent Biosciences Director Acquires Stock Options in Lieu of Cash Compensation

Director Karen Jean Ferrante acquired 2,034 stock options in Cogent Biosciences in lieu of cash compensation on October 1, 2024.

Summary

• Karen Jean Ferrante, a director of Cogent Biosciences, Inc., acquired 2,034 stock options on October 1, 2024.
• The options were granted in lieu of cash compensation for services as a director, as per the company's non-employee director compensation plan.
• The exercise price of the options is $10.75.
• The options vest immediately and expire on October 1, 2034.
• The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. The acquisition of stock options can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Director compensation packages often include stock options to align the interests of management with those of shareholders. This is a common practice in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation packages.
• The specific number of options and their valuation depend on factors such as company size, performance, and industry benchmarks.

Key Dates